Avidity Biosciences Inc (RNA) Total Business Assets

RNA (Avidity Biosciences Inc) - company brandmark

The development of drugs for genetic pathologies creates sustainable demand, ensuring high margins for Avidity Biosciences (RNA). Balance sheet assets confirm this potential, where the current mark equals 0.00. The implementation of "green" laboratory technologies minimizes hazardous waste, while the pristine condition of production lines guarantees compliance with strict regulatory standards during drug manufacturing.

Avidity Biosciences (RNA) Company Total Assets: for the period 07/04/2022 - 10/28/2026

Avidity - analytical breakdowns and key metrics (RNA)

- price and consensus price forecast:
Share Price aviditybiosciences.com|RNA - Price Target Chart
- market capitalization data:
Market Capitalization Avidity Corp|RNA - Enterprise Value
- book capitalization data:
Book Value per Share Avidity Biosciences|RNA - Book Capitalization|Market Capitalization to Book Value Ratio aviditybiosciences.com|RNA - Cumulative Company Assets
- debt and liquidity data:
Debt to Equity Avidity Biosciences|RNA - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Avidity Corp|RNA - Company Aggregate Debts|Debt to Book Value Ratio Avidity Corp
Comprehensive company analysis:Avidity Biosciences
Manufactured product of Avidity Biosciences

Total assets represent the aggregate of a company's resources, calculated reverse-engineered via ROA to identify the actual value of property and its financing structure. By analyzing consolidated asset trends, an investor can determine whether the cost of debt outweighs potential growth, which is critical for Avidity Biosciences (RNA) given its lack of revenue and high clinical trial expenditures.

Competitor analysis for Avidity Biosciences

TEM (Tempus AI, Inc) - Total Business Assets|Aggregate Company Assets Qiagen (QGEN)|Total Business Assets Ionis Pharmaceuticals, Inc.|Company Total Assets RGEN|Company Total Assets CRISPR (CRSP)|Company Total Assets WGS (GeneDx Holdings Corp.)|RARE - Company Total Assets|BEAM - Cumulative Company Assets|SRPT - Aggregate Company Assets|Twist Bio - Company Total Assets|10x (TXG) - Company Total Asset Base|Company Total Assets Intellia Therapeutics (NTLA)|Total Business Assets stoketherapeutics.com|BLFS (BioLife Solutions) - Company Total Assets|Company Total Asset Base Wave Life Sciences Ltd WVE|Cumulative Company Assets Maze Tx (MAZE)|SION - Aggregate Business Assets|PRME (Prime Medicine, Inc.) - Cumulative Company Assets|tayshagtx.com (TSHA) - Company Assets|Cumulative Company Assets uniQure QURE|MeiraGTx Holdings (MGTX) - Aggregate Asset Value|Company Total Assets Regenxbio|Aggregate Company Assets Solid Corp|OCGN (Ocugen, Inc.) - Company Total Assets|Company Total Asset Base PACB (pacb.com)|BNTC: Aggregate Company Assets|Design Therapeutics Inc - Company Assets|Aggregate Company Assets RCKT (Rocket Pharmaceuticals Inc)|FDMT - Company Total Asset Base|LXEO (lexeotx.com) - Company Total Assets|Korro Bio (KRRO) - Cumulative Company Assets|EDIT: Company Total Assets|Company Total Asset Base Silence Therapeutics PLC|ProQR Therapeutics N.V. - Company Total Assets|Company Assets CDXS (codexis.com)|SGMO - Aggregate Company Assets|Total Business Assets Nautilus Biotechnology, Inc. NAUT|MGX: Company Total Assets|DTIL - Cumulative Company Assets|Company Total Assets GBIO|BOLD (Boundless Bio Inc) - Company Assets|XCUR: Aggregate Company Assets|Company Total Asset Base IMNN|Phio Pharmaceuticals (PHIO) - Aggregate Company Assets|Aggregate Asset Value MBIO (mustangbio.com)|RNAZ - Aggregate Company Assets|Total Business Assets Bionano Genomics Inc. BNGO|Applied DNA Sciences - Company Total Assets|BLUE - Company Total Assets|Company Total Assets immunoprecise.com|OMGA (Omega Therapeutics Inc) - Total Business Assets|Aggregate Company Assets Singular Genomics Systems Inc (OMIC)|Total Business Assets Regulus|Company Total Assets SYRS|Company Total Assets telesisbio.com (TBIO)|Company Total Assets TCON (TRACON Pharmaceuticals, Inc.)|UBX - Company Total Assets